Michael Sneddon

Michael Sneddon is a seasoned executive with extensive leadership experience in the pharmaceutical and technology sectors. As Chief Executive Officer of JSK Therapeutics, Inc. since April 2021, Michael has been at the forefront of developing a novel cytotoxic drug class aimed at providing targeted, sustained anti-cancer effects. Prior to this, Michael served as Vice President at Questel after its acquisition of MultiLing Corporation, where Michael had a successful tenure from April 1988 to December 2020, including roles as President and CEO and Director of Operations. Michael holds a J.D./MBA from BYU Law School and a B.S. in Engineering from the University of Nebraska-Lincoln.